scholarly journals Cost-utility analysis of total shoulder arthroplasty: A prospective health economic study using real-world data

2021 ◽  
Author(s):  
Cécile E. Grobet ◽  
Michael C. Glanzmann ◽  
Klaus Eichler ◽  
Dominik Rickenbacher ◽  
Flurina Meier ◽  
...  
Keyword(s):  
Health Economic ◽  
Real World ◽  
Shoulder Arthroplasty ◽  
Total Shoulder Arthroplasty ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Economic Study ◽  
Utility Analysis ◽  
Real World Data ◽  
Health Economic Study

scholarly journals Cost-Utility Analysis of Arthroscopic Rotator Cuff Repair: A Prospective Health Economic Study Using Real-World Data

2020 ◽  
Vol 2 (3) ◽  
pp. e193-e205 ◽  
Author(s):  
Cécile Grobet ◽  
Laurent Audigé ◽  
Klaus Eichler ◽  
Flurina Meier ◽  
Beatrice Brunner ◽  
...  
Keyword(s):  
Health Economic ◽  
Rotator Cuff ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Economic Study ◽  
Utility Analysis ◽  
Real World Data ◽  
Health Economic Study ◽  
Arthroscopic Rotator Cuff ◽  
Cuff Repair

Is it worth repairing rotator cuff tears? A prospective cost-utility analysis using real world data

2019 ◽  
Vol 28 (6) ◽  
pp. e210-e211
Author(s):  
Matthias Flury ◽  
Cécile Grobet ◽  
Klaus Eichler ◽  
Flurina Meier ◽  
Simon Wieser ◽  
...  
Keyword(s):  
Rotator Cuff ◽  
Real World ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Rotator Cuff Tears ◽  
Utility Analysis ◽  
Real World Data ◽  
World Data

scholarly journals Health economic measures in schizophrenia research

2007 ◽  
Vol 191 (S50) ◽  
pp. s42-s45 ◽  
Author(s):  
Paul McCrone
Keyword(s):  
Health Economic ◽  
Economic Evaluation ◽  
Cost Utility ◽  
Outcome Data ◽  
Cost Utility Analysis ◽  
Economic Evaluations ◽  
Utility Analysis ◽  
Short Term ◽  
Effectiveness Analysis

BackgroundIt is essential in economic evaluations of schizophrenia interventions that all relevant costs are identified and measured appropriately Also of importance is the way in which cost data are combined with information on outcomesAimsTo examine the use of health economicsin evaluations of interventions for schizophreniaMethodsAreview of the key methods used to estimate costs and to link costs and outcomes was conductedResultsCosts fall on a number of different agencies and can be short term or long term. Cost-effectiveness analysis and cost-utility analysis are the most appropriate methods for combing cost and outcome dataConclusionsSchizophrenia poses a number of challenges for economic evaluation

scholarly journals Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE

2018 ◽  
Vol 178 (5) ◽  
pp. e356-e356
Author(s):  
S.L. Klijn ◽  
J.M.P.A. van den Reek ◽  
G. van de Wetering ◽  
A. van der Kolk ◽  
E.M.G.J. de Jong ◽  
...  
Keyword(s):  
Real World ◽  
Plaque Psoriasis ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Biologic Treatment ◽  
Real World Evidence ◽  
Treatment Sequences

Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE

2018 ◽  
Vol 178 (5) ◽  
pp. 1181-1189 ◽  
Author(s):  
S.L. Klijn ◽  
J.M.P.A. van den Reek ◽  
G. van de Wetering ◽  
A. van der Kolk ◽  
E.M.G.J. de Jong ◽  
...  
Keyword(s):  
Real World ◽  
Plaque Psoriasis ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Biologic Treatment ◽  
Real World Evidence ◽  
Treatment Sequences

scholarly journals Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Kari Jalkanen ◽  
Emma Aarnio ◽  
Piia Lavikainen ◽  
Jaana Lindström ◽  
Markku Peltonen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Health Economic ◽  
Cost Effectiveness ◽  
Cost Utility ◽  
Elevated Risk ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Payback Time ◽  
Base Scenario

Abstract Background Early identification of people at elevated risk of type 2 diabetes (T2D) is an important step in preventing or delaying its onset. Pharmacies can serve as a significant channel to reach these people. This study aimed to assess the potential health economic impact of screening and recruitment services in pharmacies in referring people to preventive interventions. Methods A decision analytic model was constructed to perform a cost-utility analysis of the expected national health economic consequences (in terms of costs and quality-adjusted life years, QALYs) of a hypothetical pharmacy-based service where people screened and recruited through pharmacies would participate in a digital lifestyle program. Cost-effectiveness was considered in terms of net monetary benefit (NMB). In addition, social return on investment (SROI) was calculated as the ratio of the intervention and recruitment costs and the net present value of expected savings. Payback time was the time taken to reach the break-even point in savings. In the base scenario, a 20-year time horizon was applied. Probabilistic and deterministic sensitivity analyses were applied to study robustness of the results. Results In the base scenario, the expected savings from the pharmacy-based screening and recruitment among the reached target cohort were 255.3 m€ (95% CI − 185.2 m€ to 717.2 m€) in pharmacy visiting population meaning 1412€ (95% CI − 1024€ to 3967€) expected savings per person. Additionally, 7032 QALYs (95% CI − 1344 to 16,143) were gained on the population level. The intervention had an NMB of 3358€ (95% CI − 1397€ to 8431€) using a cost-effectiveness threshold of 50,000 €/QALY. The initial costs were 122.2 m€ with an SROI of 2.09€ (95% CI − 1.52€ to 5.88€). The expected payback time was 10 and 8 years for women and men, respectively. Results were most sensitive for changes in effectiveness of the intervention and selected discount rate. Conclusions T2D screening and recruitment to prevention programs conducted via pharmacies was a dominant option providing both cost savings and QALY gains. The highest savings can be potentially reached by targeting recruitment at men at elevated risk of T2D.

scholarly journals A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use

2013 ◽  
Vol 11 (3) ◽  
pp. 259-274 ◽  
Author(s):  
David Price ◽  
Yumi Asukai ◽  
Jaithri Ananthapavan ◽  
Bill Malcolm ◽  
Amr Radwan ◽  
...  
Keyword(s):  
Resource Use ◽  
Real World ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
Once Daily ◽  
Real World Evidence
Sign in / Sign up

Export Citation Format

Share Document